Faslodex (fulvestrant), a new drug for metastatic breast cancer

September 2004

You'll start hearing about Faslodex (fulvestrant), a new drug for metastatic breast cancer.

It's for postmenopausal women whose cancer progresses on tamoxifen or another antiestrogen.

In these women, Faslodex delays tumour progression at least as well as the aromatase inhibitor Arimidex (anastrozole).

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get quote

Table of Contents

National Advisory Committee on Immunization is broadening the list of people who should get flu vaccine this year
Diabetes more relaxed about liver testing for Actos and Avandia
Cardiology Does Altace (ramipril) improve survival after a heart attack better than other ACE inhibitors
Cardiology increased use of spironolactone for heart failure is causing more hospitalizations and deaths
Dermatology a new prescription "nail polish" called Penlac
a new antidepressant, Cymbalta
significant new drug for alcohol dependence called Campral in the pipeline
Renal & Urology nifedipine or tamsulosin (Flomax) to help expel SMALL kidney stones
Cholesterol Vytorin, the new combo tablet for hyperlipidemia
Smoking Cessation help patients and physicians choose the right one
Hematology & Oncology Faslodex (fulvestrant), a new drug for metastatic breast cancer
Women's Health increasing levothyroxine doses by one-third as soon as pregnancy is confirmed
Women's Health pros and cons of soy for postmenopausal women
Neurology & Pain how to switch opioids